Trade names Daxas,Daliresp Routes of
administration Oral | MedlinePlus a611034 | |
 | ||
AHFS/Drugs.com Consumer Drug Information License data EU EMA: Daxas
US FDA: Roflumilast Pregnancy
category AU: B3
US: C (Risk not ruled out) | ||
Roflumilast (trade names Daxas, Daliresp) is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).
Contents
In June 2010, Daxas was approved in the EU for severe COPD associated with chronic bronchitis. In March 2011, Daliresp gained FDA approval in the US for reducing COPD exacerbations.
Medical uses
Its primary clinical use is in the prevention of exacerbations (lung attacks) in severe COPD.
Adverse effects
Common (1–10% incidence) adverse effects include:
References
Roflumilast Wikipedia(Text) CC BY-SA